Press release
Gilead Prices $3.5 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in
About this update from Gilead Sciences, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturing in 2054 and $750 million of 5.60% senior notes maturing in 2064. The offering is expected to close November 20, 2024, subject to customary closing conditions.\n\n\nGilead intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of indebtedness.\n\n\nBarclays Capital Inc. and BofA Securities, Inc. are acting as lead joint book-running managers in the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of Gilead’s effective shelf registration statement on Form S-3 (File No. 333-273745), copies of which may be obtained from:\n\n\n\n\nBarclays Capital Inc.\n\n\n\n\nc/o Broadridge Financial Solutions,\n\n\n\n\n1155 Long Island Avenue\n\n\n\n\nEdgewood, NY 11717\n\n\n\n\n(888) 603-5847\n\n\n\n\nEmail: [email protected]\n\n\n\n\n\n\n \n\n\n\n\n\n\nBofA Securities, Inc.\n\n\n\n\nNC1-022-02-25\n\n\n\n\n201 North Tryon Street\n\n\n\n\nCharlotte, NC 28255\n\n\n\n\n(800) 294-1322\n\n\n\n\nEmail: [email protected]\n\n\n\n\n\n\n\nAn electronic copy of the prospectus supplement and the accompanying base prospectus and other documents Gilead has filed with the U.S. Securities and Exchange Commission (“SEC”) may also be obtained at no charge at the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n\n\nAbout Gilead Sciences\n\n\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medici...